West Pharmaceutical Services, Inc. (WST) Income Statement

The sequential acceleration from 9.1% to 13.8% suggests that the post-pandemic destocking headwind is largely behind, and the demand for biologics and GLP-1 therapies is gaining momentum. The 21.0% growth in 2026Q1 further confirms this trend, though the guided revenue range for the next quarter implies a slight moderation, which may reflect seasonality or mix normalization. Investors should monitor whether this growth rate is sustainable as the company laps stronger comparables.

The 200 basis point year-over-year improvement in gross margin indicates that the strategic emphasis on proprietary, high-value components is paying off, as these products carry premium pricing and lower cost sensitivity. The operating margin also improved to 20.5%, suggesting that the company is not sacrificing profitability for growth. However, the sustainability of this margin expansion depends on the continued adoption of HVP and the ability to pass through raw material costs, which warrants monitoring.

The 190 basis point reduction in SG&A intensity indicates that the company is scaling its overhead efficiently relative to revenue growth. This is a positive sign for earnings quality, as it suggests that incremental revenue is flowing through to operating income at a higher rate. The operating income growth of 13.2% year-over-year in 2026Q2, despite a 13.8% revenue increase, confirms that operating leverage is being realized. However, investors should watch for any resurgence in SG&A spending as the company invests in capacity for GLP-1 demand.

The reduction in COGS intensity is a key driver of the gross margin expansion, and it appears to be a result of both higher utilization rates and a favorable product mix. The company's high-fixed-cost structure means that volume growth can significantly improve cost absorption, which is evident in the sequential improvement from 64.9% in 2026Q1 to 62.3% in 2026Q2. However, the sustainability of this trend depends on maintaining capacity utilization and managing raw material costs, which are subject to commodity price fluctuations.

The sharp recovery from 2025Q1 to 2026Q2, with operating margin expanding from 18.4% to 20.5% and net income growing from $89.8M to $154.0M, indicates that the company has successfully navigated the destocking cycle and is now benefiting from renewed demand. The EPS growth of 56.1% in 2026Q1 compared to the prior year further underscores the strength of the rebound. This inflection appears to be driven by the acceleration in high-value product sales and the resolution of customer inventory adjustments, which suggests that the company's growth trajectory is on a firmer footing.